May 1, 2017 Credit: CC0 Public Domain

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, mice that received an injection with the nanoparticle showed a 70 to 80 percent reduction in tumor size. Most significantly, mice treated with these nanoparticles showed resistance to future tumor recurrence, even when exposed to cancer cells a month later.

The results show that the newly designed nanoparticle produced potent anti-tumor immune responses to HER2-positive breast cancers. Breast cancers with higher levels of HER2 protein are known to grow aggressively and spread more quickly than those without the mutation.

"In this proof-of-concept study, we were astounded to find that the animals treated with these nanoparticles showed a lasting anti-cancer effect," says Betty Y.S. Kim, M.D., Ph.D., principal investigator, and a neurosurgeon and neuroscientist who specializes in brain tumors at Mayo Clinic's Florida campus. "Unlike existing cancer immunotherapies that target only a portion of the immune system, our custom-designed nanomaterials actively engage the entire immune system to kill cancer cells, prompting the body to create its own memory system to minimize tumor recurrence. These nanomedicines can be expanded to target different types of cancer and other human diseases, including neurovascular and neurodegenerative disorders."

Dr. Kim's team developed the nanoparticle, which she has named "Multivalent Bi-specific Nano-Bioconjugate Engager," a patented technology with Mayo Clinic Ventures, a commercialization arm of Mayo Clinic. It's coated with antibodies that target the HER2 receptor, a common molecule found on 40 percent of breast cancers. It's also coated with molecules that engage two distinct facets of the body's immune system. The nanoparticle hones in on the tumor by recognizing HER2 and then helps the immune cells identify the tumor cells to attack them.

The molecules attached to the nanoparticle rev up the body's nonspecific, clean-up cells (known as macrophages and phagocytes) in the immune system that engulf and destroy any foreign material. The design of the nanoparticle prompts these cells to appear in abundance and clear up abnormal cancer cells. These clean-up cells then relay information about the cancer cells to highly specialized T-cells in the immune system that help eradicate remaining cancer cells, while maintaining a memory of these cells to prevent cancer recurrence. It's the establishment of disease-fighting memory in the cells that makes the nanoparticle similar to a cancer vaccine. Ultimately, the body's own cells become capable of recognizing and destroying recurrent tumors.

Since the late 1990s, the field of nanomedicine has focused on developing nanoparticles as simple drug delivery vehicles that can propel chemotherapy drugs to tumors. One pitfall is that the body tends to purge the particles before they reach their destination.

"Our study represents a novel concept of designing nanomedicine that can actively interact with the immune cells in our body and modulate their functions to treat human diseases," says Dr. Kim. "It builds on recent developments in cancer immunotherapy, which have been successful in treating some types of tumors; however, most immunotherapy developed so far does not harness the power of the entire immune system. We've developed a new platform that reaches tumor cells and also recruits abundant clean-up cells for a fully potent immune response."

Future studies in the lab will explore the ability of the nanoparticle to prevent long-term recurrence of tumors, including metastases at sites distant from the primary tumor. What's more, the nanoparticle is designed to be modular, meaning it can carry molecules to fight other types of disease. "This approach hopefully will open new doors in the design of new nanomedicine-based immunotherapies," she says.

Explore further: Nanoparticles target and kill cancer stem cells that drive tumor growth

More information: Multivalent Bi-Specific Nano-Bioconjugate Engager for Targeted Cancer Immunotherapy, Nature Nanotechnology (2017). nature.com/articles/doi:10.1038/nnano.2017.69

Journal reference: Nature Nanotechnology

Provided by: Mayo Clinic

Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs. But now researchers ...

For all the success of a new generation of immunotherapies for cancer, they often leave an entire branch of the immune system's disease-fighting forces untapped. Such therapies act on the adaptive immune system, the ranks ...

Researchers from Mayo Clinic have quantified the numbers of various types of immune cells associated with the risk of developing breast cancer. The findings are published in a study in Clinical Cancer Research.

In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.

Researchers at the University of Cincinnati (UC) College of Medicine have been able to generate multifunctional RNA nanoparticles that could overcome treatment resistance in breast cancer, potentially making existing treatments ...

A team of researchers, led by the University of Minnesota, have discovered a new nano-scale thin film material with the highest-ever conductivity in its class. The new material could lead to smaller, faster, and more powerful ...

In normal conductive materials such as silver and copper, electric current flows with varying degrees of resistance, in the form of individual electrons that ping-pong off defects, dissipating energy as they go. Superconductors, ...

A pioneering new technique that encourages the wonder material graphene to "talk" could revolutionise the global audio and telecommunications industries.

An international team of scientists has developed a new way to produce single-layer graphene from a simple precursor: ethene - also known as ethylene - the smallest alkene molecule, which contains just two atoms of carbon.

Researchers at North Carolina State University have developed a new approach for manipulating the behavior of cells on semiconductor materials, using light to alter the conductivity of the material itself.

A new method combining tumor suppressor protein p53 and biomineralization peptide BMPep successfully created hexagonal silver nanoplates, suggesting an efficient strategy for controlling the nanostructure of inorganic materials.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:
Researchers develop new tumor-shrinking nanoparticle to fight cancer, prevent recurrence - Phys.Org